Author:
Kitanovski Simo,Horemheb-Rubio Gibran,Adams Ortwin,Gärtner Barbara,Lengauer Thomas,Hoffmann Daniel,Kaiser Rolf,
Abstract
Abstract
Background
Non-pharmaceutical measures to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be carefully tuned as they can impose a heavy social and economic burden. To quantify and possibly tune the efficacy of these anti-SARS-CoV-2 measures, we have devised indicators based on the abundant historic and current prevalence data from other respiratory viruses.
Methods
We obtained incidence data of 17 respiratory viruses from hospitalized patients and outpatients collected by 37 clinics and laboratories between 2010-2020 in Germany. With a probabilistic model for Bayes inference we quantified prevalence changes of the different viruses between months in the pre-pandemic period 2010-2019 and the corresponding months in 2020, the year of the pandemic with noninvasive measures of various degrees of stringency.
Results
We discovered remarkable reductions δ in rhinovirus (RV) prevalence by about 25% (95% highest density interval (HDI) [−0.35,−0.15]) in the months after the measures against SARS-CoV-2 were introduced in Germany. In the months after the measures began to ease, RV prevalence increased to low pre-pandemic levels, e.g. in August 2020 δ=−0.14 (95% HDI [−0.28,0.12]).
Conclusions
RV prevalence is negatively correlated with the stringency of anti-SARS-CoV-2 measures with only a short time delay. This result suggests that RV prevalence could possibly be an indicator for the efficiency for these measures. As RV is ubiquitous at higher prevalence than SARS-CoV-2 or other emerging respiratory viruses, it could reflect the efficacy of noninvasive measures better than such emerging viruses themselves with their unevenly spreading clusters.
Funder
German Federal Ministry of Education and Research
Universität Duisburg-Essen
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference33 articles.
1. World Health Organization. Rolling updates on coronavirus disease (COVID-19): WHO characterizes COVID-19 as a pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed 28 Aug 2020.
2. Gandhi R, Lynch J, del Rio C. Mild or Moderate COVID-19. N Engl J Med. 2020; 383(18):1757–66.
3. Sia S, Yan L-M, Chin A, Fung K, Choy K-T, Wong A, Kaewpreedee P, Perera R, Poon L, Nicholls J, et al.Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020; 583(7818):834–8.
4. Fennelly K. Particle sizes of infectious aerosols: implications for infection control. Lancet Respir Med. 2020; 8(9):914–24.
5. Van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B, Tamin A, Harcourt J, Thornburg N, Gerber S, et al.Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020; 382(16):1564–7.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献